Peptide News Digest

China Approves Lilly's Orforglipron Pill, CDC Survey on Skipped GLP-1 Doses, Health Canada Finds Bacteria in Peptides

China clears Lilly's GLP-1 pill, a CDC survey finds 44% of GLP-1 users change their doses, and Health Canada finds bacteria in an Ottawa store's peptides.

11 stories · Covering regulatory, research, industry, clinical-trials

Editor's Note

Cost shaped most of the day's GLP-1 news. In a CDC survey, 44% of U.S. adults who used a GLP-1 drug said they had changed how they took it, most often by skipping doses, and those aged 18 to 39 were nearly three times as likely as older users to cite cost. Deloitte is dropping weight-loss coverage for its U.S. staff, and a Madison pediatrician told the Cap Times that insurers often refuse the drugs to teenagers with obesity unless they already have type 2 diabetes. On the supply side, Lilly won China's first approval for a GLP-1 weight-loss pill and broke ground on a $3.5 billion Pennsylvania plant meant in part for retatrutide. Health Canada's latest seizure shows what buyers face outside those channels: bacteria in an injectable from an Ottawa wellness store whose vials included BPC-157, KLOW blends, and retatrutide, some labeled for research only. In the trials, The Lancet published full COURAGE results showing Regeneron's trevogrumab kept more lean mass during semaglutide treatment, while the stronger combination with garetosmab brought high dropout and two deaths. The three non-GLP-1 papers, on a bone-infection peptide, a frog-skin peptide for radiation burns, and jellyfish venom peptides that block amyloid clumping, are all lab or mouse work.

China Approves Lilly's Orforglipron, the First GLP-1 Weight-Loss Pill Cleared There

China's medicines regulator approved Eli Lilly's orforglipron on November 12, making it the first GLP-1 pill approved in China for weight loss, Reuters reported; until now, Chinese regulators had approved GLP-1 drugs for weight management only as injections. Lilly, which sells the drug as Foundayo in the U.S., did not comment on price. Novo Nordisk's application for its oral Wegovy was accepted in August. A J.P. Morgan analyst has forecast that annual sales of GLP-1 weight-management drugs in China could reach 30 billion yuan ($4.5 billion) within five to seven years, up from an estimated 3 billion to 4 billion yuan now.

Health Canada Finds Sphingomonas Bacteria in an Injectable Peptide Seized From Ottawa's Sage & Summit Wellness Co.

Lab testing found Sphingomonas aquatilis/melonis bacteria in an injectable peptide product seized from Sage & Summit Wellness Co. at 451 Preston Street in Ottawa after a consumer complaint that the store sold unauthorized peptides in-store and online, Health Canada said on November 12. Products seized were labeled BPC-157, hCG, a BPC-157 and TB-500 "Healing Blend," KLOW (BPC-157, TB-500, GHK-Cu, and KPV), MOTS-C, Selank, Semax, Melanotan-1, retatrutide, and tesamorelin, plus oral BPC-157 capsules, and some vials were labeled "For Research Purposes Only." The store agreed to stop selling the products, and the agency told anyone who injected one and develops fever or swelling at the injection site to seek immediate medical care.

CDC Survey: About 1 in 10 U.S. Adults Used a GLP-1 Drug in the Past Year, and 44% of Users Changed How They Took It

In CDC's Rapid Surveys System, 9.8% of 8,118 adults surveyed in July and August 2025 said they had taken a GLP-1 drug in the past 12 months, according to a report in the November 12 MMWR. Among users, 22.6% said they took a compounded version and 44% said they had changed their use from what was prescribed, most often by skipping doses (28%); 54% of users aged 18 to 39 made changes vs. 30% of those 65 and older, as did 62% of compounded-drug users vs. 36% of others. Among those who made changes, 38% cited cost and 36% availability, and about 12% of all users said they cut back or stopped because of side effects.

Deloitte Will Stop Covering GLP-1 Drugs for Weight Loss in Its U.S. Medical Plans

Deloitte will no longer cover GLP-1 drugs prescribed for weight loss and will raise deductibles and out-of-pocket maximums in most health plans, according to an internal benefits guide seen by Business Insider, which reported the change on November 12. The drugs stay covered for diabetes and other covered conditions; for weight loss, the firm is offering eMed, a virtual lifestyle program with coaching and a $125-per-prescription employer contribution. The guide covers most of Deloitte's client-facing professionals (the firm employs about 181,000 people in the U.S.), and Business Insider noted that PwC and Starbucks also cut weight-loss coverage this year.

UW Health Pediatrician Says Insurers Often Refuse GLP-1 Drugs to Teens With Obesity Unless They Already Have Type 2 Diabetes

The UW Health Kids type 2 diabetes program in Madison cared for about 25 patients in 2020 and nearly 150 in 2025, its director, Dr. Elizabeth Mann, told the Cap Times on November 12. Mann said many insurers will cover GLP-1 drugs for adolescents only after a type 2 diabetes diagnosis, not for obesity alone, and that the denials are usually plan exclusions doctors cannot appeal. At UW Health's American Family Children's Hospital, the share of new pediatric diabetes cases that were type 2 rose from 5.8% in 2018 to 16.4% in 2021.

Lilly Breaks Ground on a $3.5 Billion Lehigh Valley Plant to Make Retatrutide and Other Next-Generation Obesity Drugs

Eli Lilly broke ground on November 12 on a $3.5 billion injectable-medicine and device plant in Fogelsville, Pennsylvania, which will add capacity for next-generation obesity treatments including its investigational triple agonist retatrutide. The site is one of 10 new U.S. plants Lilly has announced since 2020 and part of a $50 billion push to expand U.S. production; Lilly expects 850 permanent jobs, about 2,000 construction jobs, and operations to begin by 2031.

Lancet Publishes COURAGE: Regeneron's Trevogrumab Preserved Lean Mass on Semaglutide, but the Garetosmab Combination Had High Dropout

In the Phase 2 COURAGE trial of 975 adults with obesity at 60 U.S. sites, people on semaglutide plus placebo lost 6.6% of their lean mass by week 26; adding trevogrumab 200 mg, an antibody against myostatin (GDF8), reduced that loss by 3.1 percentage points, and adding trevogrumab 400 mg with garetosmab reduced it by 4.5 points. In part B, trevogrumab 75 mg reduced 52-week lean-mass loss by 3.1 points vs. 7.3% on semaglutide plus placebo, while 25 mg did not differ significantly. The garetosmab combination had serious adverse events in 9% of participants, 32% discontinued treatment, 41% had muscle spasms, and both deaths in the trial occurred in that group, though investigators did not find a causal link, The Lancet paper reports.

Vivani's SLIM-1: Low-Dose Semaglutide Implant Caused No Treatment-Related Side Effects in 10 People vs. 5 of 10 on Wegovy

In the open-label Phase 1 SLIM-1 trial at one Australian site, 10 adults with overweight or obesity received a low-dose NPM-139 semaglutide implant and 10 took the 0.25 mg starting dose of Wegovy for four weeks, Vivani Medical said on November 12. None of the implant group had treatment-related adverse events vs. five on Wegovy, all gastrointestinal; drug levels peaked about 16 days after insertion vs. about 2.4 days after a Wegovy shot, and weight loss was similar at 0.79% and 0.82%. Vivani plans a Phase 2 dose-ranging weight-maintenance trial starting in 2027.

Peking University's Peptide Nanoparticle C8-IK21 Cleared Staph Bone Infections and Helped Bone Repair in Mice

Researchers designed C8-IK21, a coiled-coil peptide nanoparticle that attacks bacterial membranes and kills Staphylococcus aureus partly through lipid peroxidation. Given locally to mice with infected bone defects, it worked at doses the authors describe as safe, with no detectable resistance under the conditions tested; it also promoted bone-building cells and suppressed bone-resorbing ones, and its bone-building effect held up in organoids, the ACS Nano paper reports. The work is preclinical.

Sichuan University: Black-Spotted Frog Skin Peptide RIFSP-3 Eased Radiation Skin Injury in Mice

RIFSP-3, a peptide from the skin of the black-spotted frog Pelophylax nigromaculatus, raised survival of three human skin cell lines after radiation and, in a mouse model of radiation-induced skin injury, reduced redness, swelling, and ulcers and sped wound closure, according to a Radiation Research paper published November 10. Gene-expression analysis linked the effect to cell-cycle genes and lower inflammatory signaling, including IL-17 and TNF pathways. The authors present it as a candidate for protecting skin during cancer radiotherapy; it has not been tested in people.

Korean Genome Study Finds 35 ShK-Like Peptides in the Jellyfish Sanderia malayensis; Eight Blocked Amyloid-Beta Clumping in Lab Tests

Researchers in South Korea, including at the Personal Genomics Institute in Cheongju, assembled a 144-megabase genome of the jellyfish Sanderia malayensis and identified 35 venom peptides from the ShK-like family. Of 10 they synthesized, eight inhibited amyloid-beta oligomer and fibril formation in vitro, and several reduced amyloid-beta toxicity and reactive oxygen species in SH-SY5Y nerve cells, the Marine Drugs paper reports. No animal tests have been done yet.